Gregory Verdine

Gregory Verdine is the President and CEO of LifeMine Therapeutics and is known for coining the phrase ‘drugging the undruggable’ to describe his life mission. He led the founding team that brought LifeMine Therapeutics from concept to reality as a venture partner of WuXi Healthcare Ventures. Verdine has seamlessly moved between roles as an academic scientist, biotech entrepreneur, investor, and company executive. He serves as the Erving Professor at Harvard University and Harvard Medical School, where he made seminal contributions to understanding mechanisms of DNA repair and epigenetic DNA methylation. Verdine invented a new drug modality called stapled peptides and has founded multiple public biotech companies, including Variagenics, Enanta, Eleven Bio, Tokai, Wave Life Sciences, and Aileron. He also founded Gloucester Pharmaceuticals, a private company that was acquired by Celgene. Companies he founded have achieved FDA approval for three marketed drugs. Verdine has served on the board of directors of Enanta Pharmaceuticals, Wave Life Sciences, Warp Drive Bio, and FOG Pharmaceuticals, and led the formation and financing of Wave Life Sciences, Warp Drive Bio, and FOG Pharmaceuticals. He has managed companies as their president, chief executive officer, and chief scientific officer. Verdine earned a Ph.D. in chemistry from Columbia University and a B.S. in chemistry from St. Joseph’s University. He also served as an NIH postdoctoral fellow in molecular biology at MIT and Harvard Medical School.